Terumo (OTCMKTS:TRUMY) Corporation, trading over-the-counter under the symbol TRUMY, is a Tokyo-based medical technology company with a history dating back to its founding in 1921. Originally established as Shibuya Meisensho Co., Ltd., the company has grown into a global leader in medical devices and healthcare solutions. Headquartered in Tokyo, Terumo employs a broad network of research, manufacturing and distribution facilities spanning North America, Europe, Asia and Latin America.
Terumo’s core business is organized into several key segments, including cardiovascular systems, blood management and vascular intervention. Its cardiovascular division develops advanced devices such as guidewires, catheters and stents used in minimally invasive heart procedures. The blood management unit offers products for blood transfusion and safety, including automated blood processing systems, disposables and infection prevention devices.
Beyond its cardiovascular and blood-related offerings, Terumo provides a range of products in infusion therapy, in vitro diagnostics, and diabetes care. The company’s infusion systems deliver precise fluid administration via pumps and disposables, while its diagnostic tools support clinical laboratories with reagents and analyzers. In the diabetes segment, Terumo designs blood glucose monitoring instruments, test strips and lancing devices for home and clinical use.
Under the leadership of President and Chief Executive Officer Hisatake Shiga, Terumo places strong emphasis on research and development, investing in emerging areas such as regenerative medicine and genomic diagnostics. The company’s global footprint and diverse product portfolio position it to serve healthcare professionals and patients in both established and emerging markets, with a continued focus on innovation and quality.
MarketBeat All Access